ABSTRACT
Obesity is affecting an increasing number of individuals worldwide, but the complex interplay between genetic, environmental and lifestyle factors that control body weight is still poorly understood. Blood circulating protein are confounded readouts of the biological processes that occur in different tissues and organs of the human body. Many proteins have been linked to complex disorders and are also under substantial genetic control. Here, we investigate the associations between over 1,000 blood circulating proteins and body mass index (BMI) in three studies, including over 4,600 participants. We show that BMI is associated with widespread changes in the plasma proteome. We report 152 protein associations with BMI that replicate in at least one other study. 24 proteins also associate with a genome‐wide polygenic score (GPS) for BMI. These proteins are involved in lipid metabolism and inflammatory pathways impacting clinically relevant pathways of adiposity. Mendelian randomization suggests a bi‐directional causal relationship of BMI with three proteins (LEPR, IGFBP1, and WFIKKN2), a protein‐to‐BMI relationship for three proteins (AGER, DPT, and CTSA), and a BMI‐to‐protein relationship for 21 other proteins. Combined with animal model and tissue‐specific gene expression data, our findings suggest potential therapeutic targets and further elucidate the biological role of these proteins in pathologies associated with obesity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation. K.S. is also supported by QNRF grant NPRP11C-0115-180010. The KORA study was initiated and financed by the Helmholtz Zentrum Muenchen-German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitaet, as part of LMUinnovativ. The statements made herein are solely the responsibility of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Project agreement for this study was granted under K060/18g. All KORA participants have given written informed consent and the study was approved by the Ethics Committee of the Bavarian Medical Association. The QMDiab study was approved by the Institutional Review Boards of HMC and WCM-Q under research protocol number 11131/11). All study participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All summary statistics and association data for KORA and QMDiab are available in Supplementary Tables 2, 3, 5, and 8. The informed consent given by the study participants does not cover posting of participant level phenotype and genotype data in public databases. However, data are available upon request from KORA-gen (http://epi.helmholtz-muenchen.de/kora-gen). Requests are submitted online and are subject to approval by the KORA board.
